University of Dundee

Blood eosinophils

Jabbal, Sunny; Lipworth, Brian J.

Published in:
Clinical and Experimental Allergy

DOI:
[10.1111/cea.13057](https://doi.org/10.1111/cea.13057)

Publication date:
2017

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):
Jabbal, S., & Lipworth, B. J. (2017). Blood eosinophils: The forgotten man of inhaled steroid dose titration . *Clinical and Experimental Allergy*, 48, 93-95. <https://doi.org/10.1111/cea.13057>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Blood eosinophils: The forgotten man of inhaled steroid dose titration

Journal:	<i>Clinical and Experimental Allergy</i>
Manuscript ID	CEA-2017-0282.R1
Manuscript Type:	Research Letter
Date Submitted by the Author:	18-Oct-2017
Complete List of Authors:	Jabbal, Sunny; University of Dundee School of Medicine, Scottish Centre for Respiratory Research Lipworth, Brian; University of Dundee, Asthma & Allergy Research Group
Keywords:	asthma, eosinophils, pneumology
Additional Keywords:	nitric oxide

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Blood eosinophils: The forgotten man of inhaled steroid dose titration

¹Sunny Jabbal MB ChB, ¹Brian J Lipworth MD

¹Scottish Centre for Respiratory Research, Ninewells Hospital & Medical School, Dundee, Scotland, DD1 9SY

Correspondence to: Dr BJ Lipworth, Scottish Centre for Respiratory Research, Ninewells Hospital & Medical School, University of Dundee, Dundee, DD1 9SY. Tel: +44 1382 383188
b.j.lipworth@dundee.ac.uk

Declaration of funding: Existing departmental funds

Trial registration: Not applicable

Conflicts of Interest: BJL has received payment for giving talks from Teva ,Meda and Chiesi and Boehringer Ingelheim , for consulting activity from Chiesi ,Cipla ,Dr Reggys ,Lupin and Sandoz ,for attending meetings from Teva and Boehringer Ingelheim , for unrestricted research grants from Teva and Chiesi and Meda and multicentre grants from Chiesi , Astrazeneca ,Sanofi , Janssen and Teva. SJ has received reimbursement for attending symposia from Astra Zeneca, Chiesi Limited, NAPP, and Teva Pharmaceuticals. SJ has received fees for speaking from Chiesi Limited, NAPP, Boehringer Ingelheim, Pfizer and Astra Zeneca.

Word Count: 1012

Figures: 1

Tables: 1

22	BPD	beclometasone equivalent dose
----	------------	-------------------------------

23 **ECP** eosinophilic cationic protein

24 **FeNO** Fractional exhaled nitric oxide

25 **FEV₁** Forced expiratory volume in 1 second

26 **IL-5** Interleukin-5

27 **ICS** Inhaled corticosteroid

28 **LTRA** Leukotriene receptor antagonist

29

30

31

32

33

34

35

36

37

38

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Blood eosinophil counts which were once regarded as normal, have become of increasing interest in the era of Interleukin-5 (IL-5) asthma treatment. Blood eosinophils as low as 150 cells/ μ L have been suggested as treatment cut-offs for eosinophil depleting therapies such as mepolizumab [1], whilst a value of 300 cells/ μ L has been deemed a more pragmatic cut off by the National Institute for Health and Care Excellence (United Kingdom). In this era of eosinophil post-truths, inhaled corticosteroids (ICS), the eosinophil's oldest adversary, are very much the forgotten man.

Corticosteroids reduce the numbers of eosinophils in blood and sputum by inhibiting the expression of pro eosinophilic cytokines such as IL-5, and increase the rate of apoptosis and associated phagocytosis. It is known that titrating ICS against sputum eosinophils results in improved asthma control[2]. Whilst it is also known that sputum eosinophils correlate well with blood eosinophils [3], the effects of increasing ICS dose on blood eosinophils are less well documented [4].

We therefore wanted to know if ICS dose titration suppresses blood eosinophil counts in patients with persistent asthma. In addition, we investigated whether leukotriene receptor antagonists (LTRA) has a similar effect when used as add on therapy. Another surrogate marker of TH2 mediated inflammation is exhaled breath nitric oxide (FeNO), where it has already been demonstrated that there is a dose-response effect of ICS[5].

We, therefore, performed a pooled analysis of our own studies performed by the Scottish Centre for Respiratory Research, where we measured blood eosinophils and FeNO from a baseline of none or low dose ICS to medium dose ICS with or without LTRA. Fourteen studies were included in this analysis, and are listed in table 1. All were approved by the East of Scotland Regional Ethics Committee and registered at clinicaltrials.gov.

217 non-smoking patients with mild-moderate persistent asthma patients were included in the ICS dose titration analysis, of these 144 also received additive LTRA. Patients had a mean age of 38 years, and a mean FEV1 of 85% predicted. In all studies analysed patients must have been free from an asthma exacerbation requiring systemic corticosteroids in the three months prior to trial enrolment. In the nine out of fourteen studies included, patients had at least one positive skin prick test to a common aeroallergen, with a mean number of positive tests of two.

Baseline median low dose inhaled corticosteroid (ICS) dose was 200µg/day as beclometasone dipropionate (BDP) equivalent dose. Baseline mean eosinophils were 356 cells/µL, mean eosinophilic cationic protein (ECP) was 24.9 µg/L, and mean exhaled nitric oxide (FeNO) was 41.4 ppb. Participants were stepped up to medium dose ICS as median 800 µg/day BDP equivalent, with a median treatment duration of two weeks. Median treatment duration of additive LTRA was also two weeks.

Changes in blood eosinophils and FeNO are presented in figure 1. We observed a significant mean fall in eosinophils of 71 cells/µL (95% CI 38 to 105) $p=0.001$ comparing low versus medium dose ICS, and a further non-significant fall with LTRA amounting to 20 cells/µL. FeNO also significantly fell by 14.5ppb (95% CI 7.9 to 21.1), $p=0.001$ comparing low and medium dose ICS, but did not decrease further with addition of LTRA. Mean ECP levels for low and medium dose ICS were 24.9 µg/L and 18.8 µg/L respectively, representing a significant ($p=0.005$) decrease of 6.1 µg/L (95% CI 2.4 to 9.6), although, there were insufficient data to assess effects of LTRA. FEV₁% predicted did not significantly change between low and medium dose ICS: 1.6% (95% CI -0.5 to 3.2).

We demonstrated that ICS even at a medium dose of 800ug BDP results in a significant fall in blood eosinophils over a period of two weeks. Our data showed a non-significant further fall in

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

85 blood eosinophils amounting to 20 cells/ μ L when adding LTRA, while Laviolette et al found a
86 significant additive effect of LTRA amounting to a mean change of 40 cells [6]. In contrast
87 Greene et al found no significant additive fall with LTRA on top of ICS , albeit measuring
88 sputum rather than blood eosinophils[7]. Their study also found no significant additive effect on
89 FeNO in keeping with our data. In terms of ICS dose response, Kips et al reported significantly
90 lower sputum eosinophils comparing medium and low dose ICS, but no commensurate fall in
91 sputum ECP [8] , in contrast to our observation of a significant fall in both blood eosinophils and
92 ECP.

93 In a retrospective observational cohort study, Price et al. demonstrated that those with
94 eosinophils ≥ 400 cells/ μ L experience more severe exacerbations and have worse asthma control
95 [9]. The fundamental question therefore is whether ICS dose should be titrated against blood
96 eosinophils as a surrogate inflammatory marker, especially given that pulmonary function shows
97 a plateau in response above 400ug/day BDP equivalent dose [10]. In this regard Green et al
98 showed that titrating ICS against sputum eosinophils resulted in significantly reduced
99 exacerbations [2]; whether the same outcome would be achieved by titrating against blood
100 remains to be answered. We appreciate the limitations of our data which were only short term
101 and we did not report any outcomes of asthma control. Furthermore, the observed effect might be
102 due to possible systemic absorption from the lung, assessment of which would have required a
103 surrogate marker of systemic cortisol suppression. Finally, our study lacks a placebo arm or a
104 control arm with a fixed ICS dose, meaning we are unable to account for natural variation in
105 blood eosinophils over time. In a more sever cohort of asthma patients, it has been demonstrated
106 for subjects who have an initial blood eosinophil count above 150 cells/ μ l, 85% of them remain

1
2
3 107 above this value, even up to 56 weeks (based on four weekly blood eosinophil measurements)
4
5 108 [11].
6
7

8
9 109 As we consider ever more complex anti-inflammatory therapies as the future of asthma care, we
10
11 110 must not overlook inhaled corticosteroids and their effects on blood eosinophils as the forgotten
12
13 111 man of asthma therapy. Perhaps a randomized control trial comparing ICS dose titration against
14
15 112 conventional markers (pulmonary function, reliever use, and symptoms) versus titration against
16
17 113 blood eosinophils over one year might be worth pursuing.
18
19

20
21 114
22

23
24 115
25
26

27 116
28
29

30 117
31
32

33 118
34
35

36 119
37
38

39 120
40
41

42 121
43
44

45 122
46
47

48 123
49
50

51 124
52
53

54 125
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brightling CE, Pavord ID, Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. The Lancet Respiratory medicine 2016;4: 549-56.

2. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID, Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet (London, England) 2002;360: 1715-21.

3. Wagener AH, de Nijs SB, Lutter R, Sousa AR, Weersink EJ, Bel EH, Sterk PJ, External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 2015;70: 115-20.

4. Evans PM, O'Connor BJ, Fuller RW, Barnes PJ, Chung KF, Effect of inhaled corticosteroids on peripheral blood eosinophil counts and density profiles in asthma. The Journal of allergy and clinical immunology 1993;91: 643-50.

5. **Anderson WJ, Short PM, Williamson PA, Lipworth BJ, Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENotype trial. Chest 2012;142: 1553-61.**

6. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, Zhang J, Reiss TF, Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. American journal of respiratory and critical care medicine 1999;160: 1862-8.

- 1
2
3 148 7. Green RH, Brightling CE, McKenna S, Hargadon B, Neale N, Parker D, Ruse C, Hall IP, Pavord ID,
4
5 149 Comparison of asthma treatment given in addition to inhaled corticosteroids on airway
6
7 150 inflammation and responsiveness. The European respiratory journal 2006;27: 1144-51.
8
9
10 151 8. Kips JC, O'Connor BJ, Inman MD, Svensson K, Pauwels RA, O'Byrne PM, A long-term study of the
11
12 152 antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in
13
14 153 asthma. American journal of respiratory and critical care medicine 2000;161: 996-1001.
15
16
17 154 9. Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, Wenzel SE, Wilson AM,
18
19 155 Small MB, Gopalan G, Ashton VL, Burden A, Hillyer EV, Kerkhof M, Pavord ID, Blood eosinophil
20
21 156 count and prospective annual asthma disease burden: a UK cohort study. The Lancet Respiratory
22
23 157 medicine 2015;3: 849-58.
24
25
26 158 10. Masoli M, Weatherall M, Holt S, Beasley R, Clinical dose-response relationship of fluticasone
27
28 159 propionate in adults with asthma. Thorax 2004;59: 16-20.
29
30
31 160 11. Katz LE, Gleich GJ, Hartley BF, Yancey SW, Ortega HG, Blood eosinophil count is a useful
32
33 161 biomarker to identify patients with severe eosinophilic asthma. Annals of the American Thoracic
34
35 162 Society 2014;11: 531-6.
36
37
38
39 163
40
41
42 164
43
44
45 165
46
47
48 166
49
50
51 167
52
53
54 168
55
56
57 169
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

170

171

172 Figure legend

173 Comparison of low (200ug BDP equivalent) and medium dose (800ug BDP equivalent) inhaled
174 corticosteroid (ICS) on blood eosinophils (top) and exhaled breath nitric oxide (bottom) in n=217
175 asthma patients, depicted as means and SEM. Effects of add on therapy with leukotriene receptor
176 antagonists (LTRA) are also shown in 144 patients.

177

For Peer Review

Table 1. Source data

Reference	ICS dose (BDP µg equivalent)	Total Exposure (days)
1. Lipworth BJ et al. Am J Med 2000; 109:114-21.	600µg +/- LTRA	14
2. Aziz I et al. Chest 2000; 118:1049-58.	400-800ug	28
3. Wilson AM et al Chest 2001; 119:1021-6.	800µg +/-LTRA	14
4. Dempsey OJ et al. J Allergy Clin Immunol 2002; 109:68-74.	0-400µg	28
5. Currie GP et al. Am J Respir Crit Care Med 2003; 167:1232-8.	500µg-1000µg	21
6. Currie GP et al. Allergy 2003; 58:602-7.	0-400µg	14
7. Sims EJ et al. Br J Clin Pharmacol 2003; 56:104-11.	500µg +/-LTRA	14
8. Anderson WJ et al. Clin Sci (Lond) 2014; 127:635-43.	200 -800µg	42
9. Anderson WJ et al. Chest 2012; 142:1553-61.	200-1000µg	28
10. Lipworth BJ et al. Chest 2012; 141:607-15.	400-1200µg	365
11. Menzies D et al. Allergy 2007; 62:661-7.	200-800µg+/- LTRA	35
12. Barnes ML et al. Allergy 2007; 62:73-80.	0-400µg	70
13. Dempsey OJ et al. Chest 2002; 122:151-9.	100-400µg +/- LTRA	42
14. Wilson AM et al. Br J Clin Pharmacol 1999; 48:579-85.	1000-2000µg	8

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

178

For Peer Review

Figure legend

Comparison of low (200ug BDP equivalent) and medium dose (800ug BDP equivalent) inhaled corticosteroid (ICS) on blood eosinophils (top) and exhaled breath nitric oxide (bottom) in $n=217$ asthma patients, depicted as means and SEM. Effects of add on therapy with leukotriene receptor antagonists (LTRA) are also shown in 144 patients.

266x502mm (300 x 300 DPI)